Total raised
$69.5M
Last: PIPE 2024-09
Stage
Public
Founded
2011
Headcount
67
HQ
Rehovot
Sector
Health Tech & Life Sciences
About
Beyond Air is harnessing nitric oxide's pulmonary, antimicrobial, anti-inflammatory, and immunomodulatory mechanisms of action to deliver global access to more treatment options from hospital to home.
Its revolutionary LungFit technology platform generates nitric oxide (NO) on-demand from ambient air and safely delivers it to patients to treat a variety of lung diseases. The LungFit PH is the first and only FDA approved system with patented Ionizer technology that generates nitric oxide using room air, enabling the delivery of unlimited, on-demand nitric oxide regardless of dose or flow.
Funding history · 4 rounds · $69.5M total
2024-09
PIPE
$20.6M
2024-03
PIPE
$16.0M
2023-06
Debt Financing
$17.5M
2012-12
Seed
$1.3M
Company Intelligence Q&A
Structured intelligence from startupim data — optimized for AI retrieval and grounding.
- When did Beyond Air become a public company and on which exchange?
- Beyond Air went public on NASDAQ in August 2015, with a valuation of $11.64 million.
- What is Beyond Air's core technology for treating lung diseases?
- Beyond Air's core technology is the LungFit platform, which generates nitric oxide (NO) on-demand from ambient air for safe delivery to patients to treat various lung diseases. The LungFit PH system is FDA-approved and uses patented Ionizer technology.
- What significant debt financing did Beyond Air secure in 2023?
- In June 2023, Beyond Air secured $17.5 million in debt financing from Avenue Capital Group.
- What was a key development for Beyond Air's LungFit PH system in January 2025?
- In January 2025, Beyond Air announced that its LungFit PH system received market authorization in Australia.
- What was a notable international distribution agreement for LungFit PH in December 2025?
- In December 2025, Beyond Air signed new international LungFit PH distribution agreements, most notably in Germany and Brazil.
- What change in leadership occurred at Beyond Air in March 2026?
- In March 2026, Steve Lisi resigned as CEO of Beyond Air, and Robert Goodman, Chief Commercial Officer, was appointed as the new CEO.
- What was the outcome of Beyond Air's agreement to sell its NeuroNOS subsidiary in March 2026?
- In March 2026, Beyond Air announced the termination of its agreement to sell its NeuroNOS subsidiary to XTL Biopharmaceuticals Ltd.
- What was a significant development for Beyond Air's NeuroNOS subsidiary in September 2025?
- In September 2025, NeuroNOS, a Beyond Air affiliate, was granted FDA Orphan Drug Designation for Glioblastoma.
- What was a key development regarding Beyond Air's LungFit PH system in April 2026?
- In April 2026, Beyond Air expanded commercial access for LungFit PH through a purchasing agreement with a Top 3 National Group Purchasing Organization (GPO).
Sectors & technology
Primary sector
Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesMedical DevicesMedical Treatment & Therapeutics
Target customers
Healthcare & Life SciencesHealthcareProvidersPatientsLife SciencesPharmaceuticals
Business model
B2B
Highlights
1 Patents
Tags
medical-deviceschronic-diseaserespiratoryasthmainfectionpharmaceuticalspulmonaryinhalationchronic-patients